A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

作者：Gabriel N. Hortobágyi, Aleksandra Łacko, Joohyuk Sohn, F. Melo Cruz, Manuel Ruíz Borrego, Alexey Manikhas, Yeon H. Park, Daniil Stroyakovskiy, Denise Aysel Yardley, C.-S. Huang, P.A. Fasching, J.P. Crown, A. Bardia, S. Chia, Sun Im, M. Martín, Sherene Loi, Baichuan Xu, Sara A. Hurvitz, Carlos H. Barrios, M. Untch, R.L. Moroose, Frances M. Visco, Federico Parnizari, J.P. Zarate, Zheng Li, Simon H. Waters, Anandita Chakravartty, D. Slamon · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.10.015 · 被引用次数：107 · 研究领域：Advanced Breast Cancer Therapies、HER2/EGFR in Cancer Research、Breast Cancer Treatment Studies

BACKGROUND: NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) compared with an NSAI alone in a broad population of patients with hormone receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative early breast cancer, including a select group without nodal involvement. This is the final preplanned analysis of invasive disease-free survival (iDFS). PATIENTS AND METHODS: Premenopausal/postmenopausal women and men were randomized 1 : 1 to ribociclib (n = 2549; 400 mg/day, 3 weeks on/1 week off for 36 months) plus NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for 60 months) or NSAI alone (n = 2552). Men and premenopausal women also received goserelin (3.6 mg once every 28 days). Patients had anatomical stage IIA (N0 with additional risk factors or N1), IIB, or III disease. The primary endpoint was iDFS. Secondary efficacy endpoints were recurrence-free survival (RFS), distant DFS, and overall survival. This final iDFS analysis was planned after ∼500 events. RESULTS: At data cut-off (21 July 2023), ribociclib was stopped for 1996 patients (78.3%); 1091 (42.8%) completed 3 years of ribociclib, and ribociclib treatment was ongoing for 528 (20.7%). Median follow-up for iDFS was 33.3 months. Overall, 226 and 283 iDFS events occurred with ribociclib plus NSAI versus NSAI alone, respectively. Ribociclib plus NSAI demonstrated significant iDFS benefit over NSAI alone [hazard ratio 0.749, 95% confide...